Results 161 to 170 of about 83,985 (257)

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

Blood, 2020
Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare MA, Druker BJ, Tognon CE.   +11 more
europepmc   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, EarlyView.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. [PDF]

PLoS One, 2018
Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, Singh RR, Medeiros LJ, Luthra R, Patel KP.   +9 more
europepmc   +1 more source

TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy

Advanced Science, EarlyView.
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu, Jiawei Wang, Wei Zhang, Zhixuan Wu, Jing Chen, Yujing He, Xiyue Duan, Yaoting He, Xin Xin, Haoyi Xiang, Yijing Wang, Chengwei Wu, Yang Yi, Qing Meng, Yuqian Qiao, Kui Cheng, Xiaojun Long, Zhangfa Song   +17 more
wiley   +1 more source

A hostel for the hostile: the bone marrow niche in hematologic neoplasms. [PDF]

Haematologica, 2015
Krause DS, Scadden DT.
europepmc   +1 more source

Thermochemical Micro‐Explosion for Prompt Thrombolysis via Proximal Injection of Liquid Alkali Metal

Advanced Science, EarlyView.
We report a micro‐explosive thermochemical thrombolysis (METCT) therapy via injectable liquid alkali metal encapsulated in dimethyl silicone (LAM@oil). METCT enables prompt and safe vascular recanalization within 90 s. Critically, the LAM@oil system demonstrates significantly higher thrombolytic efficacy compared to clinically available thrombolytic ...
Xin Liao, Yi Hou, Jie Zhang, Bo Wang, Minghui Guo, Hua Qu, Wei Rao, Jing Liu   +7 more
wiley   +1 more source

[Comprehensive diagnosis of hematologic neoplasms]. [PDF]

Zhonghua Xue Ye Xue Za Zhi, 2016
Liu E, Lin Y, Wang H, Li C, Ru K.
europepmc   +1 more source

Bandgap‐Engineered PtxTey:Ag2Te Composite Quantum Dots Enable Programmable NIR‐II Imaging and Photothermal‐Immune Synergistic Therapy

Advanced Science, EarlyView.
A bandgap‐engineered PtxTey:Ag2Te quantum dot platform enables tunable NIR‐IIb emission for deep‐tissue imaging and mild photothermal therapy. Conjugation with αPD‐L1 confers dual tumor targeting and real‐time monitoring of PD‐L1 dynamics. Mild photothermal modulation induces immune reprogramming, enhancing checkpoint blockade efficacy and achieving ...
Jing Liu, Rui Xu, Quan Wu, Tian‐Xin Xiao, Lai‐Xi Zhao, Lei Sun, Ya‐Wen Zheng, Liang Dong, Zhi‐Quan Tian, Haibo Wang   +9 more
wiley   +1 more source

Detection of Central Nervous System Infiltration by Myeloid and Lymphoid Hematologic Neoplasms Using Flow Cytometry Analysis: Diagnostic Accuracy Study. [PDF]

Front Med (Lausanne), 2018
Bento LC, Correia RP, Alexandre AM, Nosawa ST, Pedro EC, Vaz ADC, Schimidell D, Fernandes GBP, Duarte CAS, Barroso RS, Bacal NS.   +10 more
europepmc   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source